Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an update.
Pharmaron Beijing Co., Ltd. has announced the scheduling of its first H Share Class Meeting of 2025, set to occur on June 20, 2025. Key resolutions to be considered include granting a repurchase mandate and increasing registered capital, which could impact the company’s financial structure and shareholder value.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company is focused on providing a range of drug development and manufacturing services.
Average Trading Volume: 8,222,394
Technical Sentiment Signal: Buy
Current Market Cap: HK$40.73B
See more data about 3759 stock on TipRanks’ Stock Analysis page.